ANKRD11 deficiency reprograms CD8(+) T cell differentiation to enhance immunity in chronic infection and cancer.

ANKRD11 deficiency in CD8+ T cells boosts antiviral and antitumor immunity, increasing effector function and tumor regression in chronic infection and cancer.

• Why it matters: CD8+ T cell dysfunction hampers clearance of hepatitis B virus and effective tumor immunity, creating a need for strategies to restore T cell activity and improve treatment outcomes.
• What they did: Using a humanized mouse model, the study knocked out ANKRD11 in CD8+ T cells, revealing enhanced proliferation, effector differentiation, and reprogramming of exhausted T cells under immunosuppressive conditions.
• The result: ANKRD11 deficiency led to increased granzyme expression, improved viral control, and tumor regression, highlighting ANKRD11 as a promising target for immunotherapy in chronic infections and cancer.